Board of Directors     |      Senior Management

Board of Directors

James Mellon
- Non-Executive Chairman
Jamie Alexander Gibson
- Executive Director and Chief Executive Officer
C. David Andrew Comba
- Independent Non-Executive Director
Julie Oates
- Independent Non-Executive Director
Stawell Mark Searle
- Independent Non-Executive Director
Jayne Allison Sutcliffe
- Non-Executive Director

James Mellon (alias: Jim Mellon)
Non-Executive Chairman

James Mellon, British, was appointed as an Executive Director of the Company in July 1991, and was re-designated as a Non-Executive Director in May 2002, and is currently the Non-Executive Chairman of the Board of Directors.

He holds a Master’s degree in Politics, Philosophy and Economics from Oxford University and, since graduating in 1978, his entire career has been spent in asset management. Mr Mellon worked for GT Management Plc from 1978 to 1984. In July 1984, he joined the Thornton Group where he was Managing Director of the Asian operation. From 1988 to 1990, he was an executive director of Tyndall Holdings Plc responsible for business expansion and corporate development.

In 1990, Mr Mellon co-founded and became Chief Executive of Regent Pacific Group. In 1994, he became Chairman of Regent Pacific Group. Mr Mellon has over 20 years' investment experience in Asia. He specialises in the development and restructuring of international investment vehicles, and travels extensively across the region on company visits and fact-finding missions.

He is also director of certain subsidiaries of Regent Pacific Group. Mr Mellon is also: (i) a non-executive director of Agronomics Limited (having stepped down as the chairman of its board on 31 May 2019 and remaining as a non-executive director), a non-executive director of Condor Gold plc and the executive chairman of the board of Manx Financial Group plc, all of which are listed on the London Stock Exchange AIM ("AIM"); (ii) a non-executive director of Bradda Head Holdings Limited (which was delisted on the Over the Counter Bulletin Board of NASDAQ of the United States and the Canadian Securities Exchange); (iii) a non-executive director of Portage Biotech Inc (which is dually listed on the Over the Counter Bulletin Board of NASDAQ of the United States and the Canadian Securities Exchange); and (iv) the non-executive chairman of the board of Speymill Deutsche Immobilien Company plc (which was de-listed from AIM on 31 May 2011).

He was formerly: (1) the non-executive chairman of the board of FastForward Innovations Limited (An AIM-listed company), having stepped down and ceased to be a director on 22 August 2019; (2) the non-executive chairman of the board of Rivington Street Holdings Limited (which was de-listed from ICAP Securities and Derivatives Exchange (ISDX) in the United Kingdom on 3 April 2014 and was dissolved on 20 October 2017); (3) the non-executive chairman of the board of SalvaRx Group Plc (which was de-listed from AIM on 9 January 2020), which, following a group restructuring in March 2017, disposed of all its investments and business interests to its subsidiary, namely SalvaRx Limited; (4) the executive chairman of the board of Speymill plc (which was de-listed from AIM on 2 February 2015 and was dissolved on 20 October 2017); and (5) a non-executive director of West African Minerals Corporation (then an AIM-listed company, and now listed on the London Stock Exchange Standard as Okyo Pharma Limited), having resigned on 13 November 2017.




Senior Management

   Hong Kong

David Samuel Church, LLB, BEc
Head of Mergers and Acquisitions and General Counsel

David joined Regent Pacific Group in 2008. He is also director of a number of subsidiaries of Regent Pacific Group. David has more than 19 years’ experience in mergers and acquisitions and corporate finance in Australia, the UK, Europe and Asia with expertise across multiple sections. David has worked on domestic and international corporate transactions as well as major international equity offerings for corporates and investment banks. He has over 13 years’ experience in Asia including transactions in Hong Kong, Korea, the PRC, Singapore, Indonesia, Malaysia and the Philippines. David has acted and advised on some of the most high profile M&A transactions in Europe and Asia. He is qualified and has practiced as a solicitor in Australia, with Clayton Utz, and in the UK and Hong Kong, with Linklaters.
  Paul Eric Jones, BA, MBA
Investment Director

Paul has 30 years of experience in the energy industry and corporate finance. This has included various professional disciplines encompassing fund management, banking and business development. Before joining Regent Pacific Group in April 2011, Paul was employed for six years with a Canadian private equity fund, where he was principally engaged in evaluating investment opportunities on behalf of the firm’s investors and managing a portfolio of public and private securities. Prior thereto, Paul was a Director in the energy lending group at the Canadian Imperial Bank of Commerce (CIBC) where he specialised in debt financing and providing advisory services to oil and gas producers. Previous to his banking career, Paul was a financial analyst with TC Energy Corp. (a Canadian power generation and energy transmission company), where he was responsible for initiatives related to bond issuance, project finance, capital budgeting and investor relations. Paul holds a Bachelor of Arts and a Master of Business Administration (Finance), both from the University of Calgary.


   United Kingdom

Professor Michael Grant Wyllie, BSc, PhD, DSc
Chief Scientific Officer

Prof Wyllie has particular responsibility for the process of securing approvals of the product, regulatory compliance and assisting the Chief Executive Officer in the commercial development of Fortacin™ of Plethora Solutions Holdings plc (“Plethora”). Prof Wyllie is a co-founder of Plethora. He has over 30 years of experience in senior management level positions within the pharmaceutical industry, with Wyeth and Pfizer. He has considerable hands-on experience in all aspects of the drug discovery and development process, and has been involved with new project inception, drug discovery and safety testing, early and late stage clinical development, regulatory filing, and the successful commercialisation of products, including Cardura® (doxazosin), Enablex® (darifenacin)and Viagra® (sildenafil). Prof Wyllie sits on the Clinical Trial Design and Future Therapies in BPH Committees of the World Health Organisation International Consultations on Urological Disease and the International Advisory Panel to The University of Strathclyde. He is an assistant editor of the British Journal of Urology in the Sexual Medicine Section. He has over 200 publications and is the named inventor of over 80 patents.